Charles River Laboratories International (NYSE:CRL) Price Target Raised to $295.00

Charles River Laboratories International (NYSE:CRL) had its target price upped by Mizuho from $264.00 to $295.00 in a research report sent to investors on Friday, Marketbeat Ratings reports. They currently have a neutral rating on the medical research company’s stock.

Several other research firms have also recently commented on CRL. JPMorgan Chase & Co. raised shares of Charles River Laboratories International from a “neutral” rating to an “overweight” rating and raised their target price for the company from $180.00 to $310.00 in a research note on Thursday, August 6th. Piper Sandler set a $300.00 price target on shares of Charles River Laboratories International in a research report on Monday, August 10th. Argus set a $330.00 target price on shares of Charles River Laboratories International in a research note on Thursday, September 17th. Morgan Stanley raised their price target on shares of Charles River Laboratories International from $260.00 to $300.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Finally, Royal Bank Of Canada boosted their target price on Charles River Laboratories International from $215.00 to $282.00 and gave the stock an “outperform” rating in a report on Thursday, August 6th. Twelve investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $287.06.

Charles River Laboratories International Price Performance

Shares of CRL opened at $292.49 on Friday. The stock has a fifty day moving average price of $270.45 and a 200 day moving average price of $213.29. The company has a market cap of $13.96 billion, a P/E ratio of -60.31, a PEG ratio of 2.85 and a beta of 1.40. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. Charles River Laboratories International has a 12 month low of $145.32 and a 12 month high of $303.30.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $980.53 million. During the same quarter last year, the company earned $3.12 EPS. The company’s revenue for the quarter was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, research analysts forecast that Charles River Laboratories International will post 11.42 earnings per share for the current year.

Insider Activity at Charles River Laboratories International

In related news, CEO Birgit Girshick sold 6,500 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total value of $1,819,350.00. Following the transaction, the chief executive officer owned 36,013 shares in the company, valued at $10,080,038.70. This trade represents a 15.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director James Foster sold 33,561 shares of Charles River Laboratories International stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $300.00, for a total transaction of $10,068,300.00. Following the sale, the director owned 31,596 shares of the company’s stock, valued at approximately $9,478,800. This represents a 51.51% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 90,990 shares of company stock valued at $25,731,388 in the last three months. 1.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Charles River Laboratories International

A number of institutional investors have recently made changes to their positions in CRL. Continuum Advisory LLC acquired a new position in shares of Charles River Laboratories International during the 2nd quarter worth about $30,000. SHP Wealth Management bought a new stake in shares of Charles River Laboratories International during the fourth quarter worth $85,000. Eurizon Capital SGR S.p.A. acquired a new stake in shares of Charles River Laboratories International in the 4th quarter valued at about $104,000. Trust Asset Management LLC acquired a new stake in Charles River Laboratories International in the 2nd quarter valued at approximately $129,000. Finally, Hilltop National Bank raised its holdings in shares of Charles River Laboratories International by 28.7% in the second quarter. Hilltop National Bank now owns 569 shares of the medical research company’s stock valued at $129,000 after purchasing an additional 127 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Charles River Laboratories International

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Analysts raised their price targets. Royal Bank of Canada lifted its target from $282 to $322 and maintained an “outperform” rating, while Robert W. Baird raised its target from $291 to $334 and also rated CRL “outperform.” These revisions imply roughly 10% to 14% additional upside from the referenced price.
• Positive Sentiment: Investor Day provided stronger long-term growth visibility. Charles River reaffirmed its fiscal 2026 revenue outlook at approximately $3.9 billion and raised EPS guidance to $11.45, above the $11.33 analyst consensus. The company also introduced 2030 growth targets, helping drive a recent rally in the stock. Charles River Laboratories Stock Rises 6% After Unveiling 2030 Growth Targets
• Positive Sentiment: Investor reaction has been favorable. Reports indicated CRL rose about 5% to 6% following the company’s Investor Day presentation, reflecting investor confidence in the updated 2026 outlook and longer-term targets. Charles River Laboratories Reaffirms Fiscal 2026 Guidance; Issues 2030 Growth Projections
• Neutral Sentiment: Mizuho raised its target but remained cautious. The firm increased its target from $264 to $295 but kept a “neutral” rating, suggesting limited upside from the referenced price and a more balanced risk-reward assessment.
• Negative Sentiment: Some of the good news may already be priced in. An investor analysis characterized the Investor Day as positive but argued that the improved outlook is fully reflected in CRL’s valuation. This may explain why the stock has decreased modestly despite favorable announcements. Charles River Laboratories: Positive Investor Day Is Fully Priced In

About Charles River Laboratories International

Charles River Laboratories International, Inc is a global provider of drug discovery, nonclinical development and laboratory services for pharmaceutical, biotechnology and medical device companies, as well as academic and government research institutions. The company supports customers throughout the development process, from early-stage research and target identification through preclinical testing and regulatory preparation.

Its offerings include research models and related products, discovery and development services, toxicology and safety assessment, efficacy testing, bioanalysis, and laboratory testing.